clinical trial · NCT06518538
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer Stage IVCPI-613, modified Folfirinox
brief summary
Open label, randomized phase II study to evaluate efficacy and safety of CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
started
Aug 15, 2024
primary completion
Aug 1, 2026
completion
Nov 1, 2026
last updated
Aug 15, 2024
official title
A Phase 2 Single Center Open-Label Trial to Evaluate Efficacy and Safety of Devimistat in Combination With Modified FOLFIRINOX (mFFX) in 2nd Line Patients With Metastatic Adenocarcinoma of the Pancreas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol